ArticleBritish journal of cancer2013
Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Systematic Review of the Prognostic Role of the Immune System After Surgery of Colorectal Liver Metastases.Frontiers in oncology · 2019Pooled it
- Proteomic Differentiation of Colorectal Cancer From Normal Tissue via Ex Vivo E-Biopsy: A Novel Approach to Molecular Sampling for Diagnostic Precision.Cancer medicine · 2026Article
- Inhibition of the SERPINB5/HSP90AA1 axis restrains the proliferation and invasion of rectal cancer.World journal of gastroenterology · 2025Article
- The paradoxical role of SERPINB5 in gastrointestinal cancers: oncogene or tumor suppressor?Molecular biology reports · 2025Review
- Article
- Biomarker Identification through Proteomics in Colorectal Cancer.International journal of molecular sciences · 2024Review
- Correlation between Maspin Levels in Different Biological Samples and Pathologic Features in Colorectal Adenocarcinomas.Life (Basel, Switzerland) · 2023Article
- The dynamic dysregulated network identifies stage-specific markers during lung adenocarcinoma malignant progression and metastasis.Molecular therapy. Nucleic acids · 2022Article
- The Role of Selected Serpins in Gastrointestinal (GI) Malignancies.Journal of clinical medicine · 2022Review
- Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases.International journal of molecular sciences · 2022Review
- Molecular Network of Colorectal Cancer and Current Therapeutic Options.Frontiers in oncology · 2022Review
- Article
- Systems-level biomarkers identification and drug repositioning in colorectal cancer.World journal of gastrointestinal oncology · 2021Review
- A predictive model for early recurrence of colorectal-cancer liver metastases based on clinical parameters.Gastroenterology report · 2021Article
- Review
- Maspin as a Prognostic Marker for Early Stage Colorectal Cancer With Microsatellite Instability.Frontiers in oncology · 2020Article
- B Cells as Prognostic Biomarker After Surgery for Colorectal Liver Metastases.Frontiers in oncology · 2020Article
- Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research.Frontiers in oncology · 2019Review
- Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker.BMC cancer · 2018Article
- Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the factors that drive metastasis formation in colorectal cancer (CRC). Here, we set out to identify genes and proteins in patients with colorectal liver metastases that correlate with early disease recurrence. Such factors may predict a propensity for metastasis in earlier stages of CRC.
methodsGene expression profiling and proteomics were used to identify differentially expressed genes/proteins in resected liver metastases that recurred within 6 months following liver surgery vs those that did not recur for >24 months. Expression of the identified genes/proteins in stage II (n=243) and III (n=176) tumours was analysed by immunohistochemistry on tissue microarrays. Correlation of protein levels with stage-specific outcome was assessed by uni- and multivariable analyses.
resultsBoth gene expression profiling and proteomics identified Maspin to be differentially expressed in colorectal liver metastases with early (<6 months) and prolonged (>24 months) time to recurrence. Immunohistochemical analysis of Maspin expression on tumour sections revealed that it was an independent predictor of time to recurrence (log-rank P=0.004) and CRC-specific survival (P=0.000) in stage III CRC. High Maspin expression was also correlated with mucinous differentiation. In stage II CRC patients, high Maspin expression did not correlate with survival but was correlated with a right-sided tumour location.
conclusionHigh Maspin expression correlates with poor outcome in CRC after spread to the local lymph nodes. Therefore, Maspin may have a stage-specific function possibly related to tumour cell dissemination and/or metastatic outgrowth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.